The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•12 April 2026•

1 min read

Dorfman’s Q1 2026 'Casualty List' Highlights Recovery Potential in Five Battered Stocks

Logos of Mineralys Therapeutics and Jefferies on an orange background with financial charts, chemical structures, microscopes, lab equipment, vials, and pills.

Key Facts

1John Dorfman identified five stocks (Humana, Cognizant, Abercrombie, Harmony Biosciences, and Thor) that dropped 20% or more in the first quarter.

Financial analyst John Dorfman has released his 'Casualty List' for the first quarter of 2026, identifying five stocks that experienced significant declines of 20% or more. The list includes Humana Inc. (HUM), Cognizant Technology Solutions (CTSH), Abercrombie & Fitch Co. (ANF), Harmony Biosciences Holdings (HRMY), and Thor Industries (THO). Despite their recent underperformance, Dorfman views these equities as undervalued opportunities poised for a potential rebound. This contrarian strategy is backed by historical success, as the previous year's recommendations achieved an impressive average return of 91%. The selection focuses on companies with solid fundamentals that have been disproportionately hit by temporary market challenges. Investors are now closely watching these tickers as potential value plays in anticipation of a price recovery.